IP Library › Granted Patent US 12,329,734
Granted Patent B2
US 12,329,734 · App. 18/592,262 · Granted Jun 17, 2025

Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow

Inventor: Gary Millet (Salt Lake City, UT)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/22A61K9/0053A61K31/047A61K31/19A23V2200/3322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,734
App. No.
18/592,262
Granted
Jun 17, 2025
Kind
B2
Abstract

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Claims (34)

1. A method for raising blood ketone levels in a subject to induce and maintain a state of flow in the subject, comprising:

administering a composition comprising optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate in order to enhance brain metabolism, improve mental alertness, improve cognitive function, and improve mood,

wherein the composition provides about 0.5 g to about 30-25 g of S-beta-hydroxybutyrate to the subject.

2. The method of claim 1 , wherein the composition provides about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams of S-beta-hydroxybutyrate.

3. The method of claim 1 , wherein the composition comprises optically pure S-beta-hydroxybutyrate, which includes a mixture of at least one optically pure S-beta-hydroxybutyrate salt and optically pure S-beta-hydroxybutyric acid.

4. The method of claim 1 , wherein the composition comprises a non-racemic mixture enriched in S-beta-hydroxybutyrate relative to R-beta-hydroxybutyrate, wherein the non-racemic mixture includes:

at least one S-beta-hydroxybutyrate salt;

at least one R-beta-hydroxybutyrate salt; and

at least one of S-beta-hydroxybutyric acid or R-beta-hydroxybutyric acid.

5. The method of claim 1 , wherein the composition comprises a non-racemic mixture that contains 50.5% to 99.5% by enantiomeric equivalents of S-beta-hydroxybutyrate and 49.5% to 0.5% by enantiomeric equivalents of R-beta-hydroxybutyrate, or 51% to 99% by enantiomeric equivalents of S-beta-hydroxybutyrate and 49% to 1% by enantiomeric equivalents of R-beta-hydroxybutyrate, or 52% to 98% by enantiomeric equivalents of S-beta-hydroxybutyrate and 48% to 2% by enantiomeric equivalents of R-beta-hydroxybutyrate.

6. The method of claim 1 , wherein the composition comprises 75% to 99.9% by molar equivalents of total beta-hydroxybutyrate salt and 25% to 0.1% by molar equivalents of total beta-hydroxybutyric acid, or 80% to 99.8% by molar equivalents of total beta-hydroxybutyrate salt and 20% to 0.2% by molar equivalents of total beta-hydroxybutyric acid.

7. The method of claim 1 , wherein the composition comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of S-beta-hydroxybutyrate.

8. The method of claim 1 , further comprising at least one short chain fatty acid having less than 6 carbons, or a mono-, d i-or triglyceride of the at least one short chain fatty acid.

9. The method of claim 1 , further comprising at least one supplement selected from vitamin, mineral, caffeine, theobromine, nootropic, and herbal supplement.

10. The method of claim 1 , wherein the composition induces the state of flow in the subject for at least about 30 minutes, or at least about 60 minutes, at least about 90 minutes, at least about 120 minutes, at least about 180 minutes, at least about 240 minutes, or at least about 300 minutes.

11. The method of claim 1 , wherein the composition is provided as a kit for administering ketone bodies to a subject, comprising:

a container in which the composition is placed; and

a measuring device configured to hold therein a unit dose, or fraction thereof, of the composition, wherein a unit dose of the composition contains about 0.5 g to about 30-25 g of S-beta-hydroxybutyrate.

12. The method of claim 11 , wherein the container is selected from the group consisting of carton, box, can, jar, bag, pouch, bottle, jug, liquid squeeze bottle with integrated measuring device, and keg, and wherein the measuring device is selected from the group consisting of cup, scoop, syringe, dropper, spatula, spoon, and colonic irrigation device.

13. A method for raising blood ketone levels in a subject to induce and maintain a state of flow in the subject, comprising:

administering a composition comprising optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate in order to enhance brain metabolism, improve mental alertness, improve cognitive function, and improve mood,

wherein the composition is provided as or in a tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, or suppository,

wherein the composition provides about 0.5 g to about 25 g of S-beta-hydroxybutyrate to the subject.

14. The method of claim 12 , wherein the composition contains about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams of S-beta-hydroxybutyrate.

15. The method of claim 12 , wherein the composition comprises at least one lithium, sodium, potassium, calcium, magnesium, or amino acid salt of S-beta-hydroxybutyrate.

16. The method of claim 12 , further comprising at least one short chain fatty acid having less than 6 carbons, or a mono-, d i-or triglyceride of the at least one short chain fatty acid.

17. The method of claim 12 , further comprising at least one supplement selected from vitamin, mineral, caffeine, theobromine, nootropic, and herbal supplement.

18. A method for raising blood ketone levels in a subject to induce and maintain a state of flow in the subject, comprising:

administering to the subject a composition comprising:

a dietetically or pharmaceutically acceptable carrier selected from the group consisting of tablet, capsule, powder, food product, food additive, flavored beverage, vitamin fortified beverage, non-alcoholic beverage, flavored beverage additive, vitamin fortified beverage additive, non-alcoholic beverage additive, candy, sucker, pastille, food supplement, flavored mouth spray, and suppository; and

optically pure S-beta-hydroxybutyrate or a non-racemic mixture of S-beta-hydroxybutyrate and R-beta-hydroxybutyrate containing more than 50% and less than 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and less than 50% and more than 0% by enantiomeric equivalents of R-beta-hydroxybutyrate,

wherein the composition provides about 0.5 g to about 25 g of S-beta-hydroxybutyrate in order to enhance brain metabolism, improve mental alertness, improve cognitive function, and improve mood.

19. The method of claim 17 , wherein the composition provides about 0.75 gram to about 20 grams, or about 1 gram to about 15 grams, or about 1.5 grams to about 12 grams of S-beta-hydroxybutyrate.

20. The method of claim 17 , further comprising at least one supplement selected from vitamin, mineral, caffeine, theobromine, nootropic, herbal supplement, and short-chain fatty acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 066705/0681 →
Continuity (9)
Continuation In Part 18218519 · Jul 5, 2023
Continuation In Part 17555724 · Dec 20, 2021
Continuation 17130498 · Dec 22, 2020
Continuation In Part 16783886 · Feb 6, 2020
Continuation In Part 16272192 · Feb 11, 2019
Continuation In Part 16224485 · Dec 18, 2018
Division 15936849 · Mar 27, 2018
Provisional Application 62607578 · Dec 19, 2017
Related Publication 20240197668A1 · Jun 20, 2024
References Cited (400)
US 2238149A · Aeckerle · 1941 [cited by applicant]
US 2976073A · Russell et al. · 1961 [cited by applicant]
US 4139761A · Obrowski · 1979 [cited by applicant]
US 4224503A · Gijzel et al. · 1980 [cited by applicant]
US 4292499A · Kleinschmidt et al. · 1981 [cited by applicant]
US 4627808A · Hughes · 1986 [cited by applicant]
US 4771074A · Lammerant et al. · 1988 [cited by applicant]
US 4969393A · Mahlich et al. · 1990 [cited by applicant]
US 4997976A · Brunengraber et al. · 1991 [cited by applicant]
US 5093044A · Wretlind et al. · 1992 [cited by applicant]
US 5100677A · Veech · 1992 [cited by applicant]
US 5116868A · Chen et al. · 1992 [cited by applicant]
US 5288512A · Seiden · 1994 [cited by applicant]
US 5292774A · Hiraide et al. · 1994 [cited by applicant]
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 6031000A · Nissen et al. · 2000 [cited by applicant]
US 6207856B1 · Veech · 2001 [cited by applicant]
US 6217915B1 · Luchansky et al. · 2001 [cited by applicant]
US 6232345B1 · Hiraide et al. · 2001 [cited by applicant]
US 6316038B1 · Veech · 2001 [cited by applicant]
US 6323237B1 · Veech · 2001 [cited by applicant]
US 6380244B2 · Martin et al. · 2002 [cited by applicant]
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 6706756B1 · Fitzpatrick et al. · 2004 [cited by applicant]
US 6835750B1 · Henderson · 2004 [cited by applicant]
US 7351736B2 · Veech · 2008 [cited by applicant]
US 7807718B2 · Hashim et al. · 2010 [cited by applicant]
US 7891287B2 · Miller · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8101653B2 · Veech · 2012 [cited by applicant]
US 8124589B2 · Henderson · 2012 [cited by applicant]
US 8344896B2 · Ozanne · 2013 [cited by applicant]
US 8426468B2 · Henderson · 2013 [cited by applicant]
US 8642654B2 · Clarke et al. · 2014 [cited by applicant]
US 8748400B2 · Henderson · 2014 [cited by applicant]
US 9138420B2 · D'Agostino et al. · 2015 [cited by applicant]
US 9186340B2 · Andrews et al. · 2015 [cited by applicant]
US 9211275B2 · Clarke et al. · 2015 [cited by applicant]
US 9435566B2 · Hill et al. · 2016 [cited by applicant]
US 9675577B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9717767B2 · Carpenter et al. · 2017 [cited by applicant]
US 9795580B2 · Weeber et al. · 2017 [cited by applicant]
US 9808481B2 · Ritter et al. · 2017 [cited by applicant]
US 9925164B1 · Hashim · 2018 [cited by applicant]
US 9957246B2 · Stinchcomb et al. · 2018 [cited by applicant]
US 10022409B2 · Carpenter et al. · 2018 [cited by applicant]
US 10051880B2 · Clarke et al. · 2018 [cited by applicant]
US 10088197B2 · Hamagami et al. · 2018 [cited by applicant]
US 10245242B1 · Millet · 2019 [cited by applicant]
US 10245243B1 · Millet · 2019 [cited by applicant]
US 10278961B2 · Lowery et al. · 2019 [cited by applicant]
US 10292592B2 · Marshall et al. · 2019 [cited by applicant]
US 10292952B2 · Millet · 2019 [cited by applicant]
US 10407331B2 · Kamito et al. · 2019 [cited by applicant]
US 10512615B1 · Millet · 2019 [cited by applicant]
US 10588876B2 · Millet · 2020 [cited by applicant]
US 10588877B2 · Arnold · 2020 [cited by applicant]
US 10596128B2 · Millet · 2020 [cited by applicant]
US 10596129B2 · Millet · 2020 [cited by applicant]
US 10596130B2 · Millet · 2020 [cited by applicant]
US 10596131B2 · Millet · 2020 [cited by applicant]
US 10660958B2 · Clarke · 2020 [cited by applicant]
US 10736861B2 · Millet · 2020 [cited by applicant]
US 10792269B2 · Hashim · 2020 [cited by applicant]
US 10925843B2 · Millet · 2021 [cited by applicant]
US 10973786B2 · Millet · 2021 [cited by applicant]
US 10980764B1 · D'Agostino et al. · 2021 [cited by applicant]
US 10980772B2 · Millet · 2021 [cited by applicant]
US 11020362B2 · Millet · 2021 [cited by applicant]
US 11026929B2 · Lowery et al. · 2021 [cited by applicant]
US 11033553B2 · Millet · 2021 [cited by applicant]
US 11103470B2 · Millet · 2021 [cited by applicant]
US 11129802B2 · Millet · 2021 [cited by applicant]
US 11173138B2 · Lowery et al. · 2021 [cited by applicant]
US 11185518B2 · Millet · 2021 [cited by applicant]
US 11202769B2 · Millet · 2021 [cited by applicant]
US 11241403B2 · Millet · 2022 [cited by applicant]
US 11690817B2 · Millet · 2023 [cited by applicant]
US 11793778B2 · Millet · 2023 [cited by applicant]
US 11806324B2 · Millet · 2023 [cited by applicant]
US 11944598B2 · Millet · 2024 [cited by examiner]
US 11950616B2 · Millet · 2024 [cited by applicant]
US 20010014696A1 · Veech · 2001 [cited by applicant]
US 20010018866A1 · Fischer · 2001 [cited by applicant]
US 20010041736A1 · Veech · 2001 [cited by applicant]
US 20020013339A1 · Martin et al. · 2002 [cited by applicant]
US 20020124370A1 · Deckert et al. · 2002 [cited by applicant]
US 20030022937A1 · Veech · 2003 [cited by applicant]
US 20040126366A1 · Kaddurah-Daouk et al. · 2004 [cited by applicant]
US 20040138293A1 · Werner et al. · 2004 [cited by applicant]
US 20040266872A1 · Veech · 2004 [cited by applicant]
US 20050129783A1 · McCleary et al. · 2005 [cited by applicant]
US 20050169968A1 · Elmaleh et al. · 2005 [cited by applicant]
US 20060165777A1 · Solomon et al. · 2006 [cited by applicant]
US 20060275253A1 · Ushida et al. · 2006 [cited by applicant]
US 20070029913A1 · Chen · 2007 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20070179197A1 · Henderson · 2007 [cited by applicant]
US 20080058416A1 · Greenwood et al. · 2008 [cited by applicant]
US 20080287372A1 · Henderson · 2008 [cited by applicant]
US 20090131475A1 · Uesugi et al. · 2009 [cited by applicant]
US 20090253781A1 · Veech · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20090325984A1 · Costentin et al. · 2009 [cited by applicant]
US 20100041751A1 · Henderson · 2010 [cited by applicant]
US 20100056631A1 · Hisamura et al. · 2010 [cited by applicant]
US 20100113494A1 · Hu et al. · 2010 [cited by applicant]
US 20100197758A1 · Andrews et al. · 2010 [cited by applicant]
US 20100210726A1 · Kuriyama · 2010 [cited by applicant]
US 20100298294A1 · Clarke et al. · 2010 [cited by applicant]
US 20110111049A1 · Andrews et al. · 2011 [cited by applicant]
US 20110237666A1 · Clarke et al. · 2011 [cited by applicant]
US 20110287114A1 · Johnson · 2011 [cited by applicant]
US 20120053240A1 · Rathmacher et al. · 2012 [cited by applicant]
US 20120071548A1 · Veech · 2012 [cited by applicant]
US 20120171165A1 · Buck et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20130079406A1 · Veech · 2013 [cited by applicant]
US 20130337116A1 · Petralia · 2013 [cited by applicant]
US 20140256808A1 · Henderson · 2014 [cited by applicant]
US 20140329893A1 · Veech · 2014 [cited by applicant]
US 20140350105A1 · D'Agostino et al. · 2014 [cited by applicant]
US 20140352728A1 · Svensson · 2014 [cited by applicant]
US 20150018415A1 · Veech · 2015 [cited by applicant]
US 20150063140A1 · Yi et al. · 2015 [cited by applicant]
US 20150065571A1 · Clarke et al. · 2015 [cited by applicant]
US 20150132280A1 · Lopez et al. · 2015 [cited by applicant]
US 20150144074A1 · Fujimoto et al. · 2015 [cited by applicant]
US 20150320809A1 · Carpenter et al. · 2015 [cited by applicant]
US 20150363750A1 · Svensson et al. · 2015 [cited by applicant]
US 20160193173A1 · Clarke et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160263071A1 · Borges et al. · 2016 [cited by applicant]
US 20160272603A1 · Kravchenko et al. · 2016 [cited by applicant]
US 20170020844A1 · Galinski · 2017 [cited by applicant]
US 20170029650A1 · Veling et al. · 2017 [cited by applicant]
US 20170172969A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170258745A1 · Millet · 2017 [cited by applicant]
US 20170266148A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170290792A1 · Cavaleri · 2017 [cited by applicant]
US 20170296501A1 · Lowery et al. · 2017 [cited by applicant]
US 20170296520A1 · Lowery et al. · 2017 [cited by applicant]
US 20170298339A1 · Hanson et al. · 2017 [cited by applicant]
US 20170304564A1 · Dehaan et al. · 2017 [cited by applicant]
US 20180020699A1 · Steup · 2018 [cited by applicant]
US 20180021274A1 · Arnold · 2018 [cited by applicant]
US 20180021281A1 · Berger · 2018 [cited by applicant]
US 20180055797A1 · Llosa et al. · 2018 [cited by applicant]
US 20180057846A1 · Llosa et al. · 2018 [cited by applicant]
US 20180195096A1 · Veech et al. · 2018 [cited by applicant]
US 20180214399A1 · Spector et al. · 2018 [cited by applicant]
US 20180238586A1 · Sugatani et al. · 2018 [cited by applicant]
US 20190099394A1 · Ari et al. · 2019 [cited by applicant]
US 20190151267A1 · Millet · 2019 [cited by applicant]
US 20190167613A1 · Millet · 2019 [cited by applicant]
US 20190167614A1 · Millet · 2019 [cited by applicant]
US 20190177673A1 · Llosa et al. · 2019 [cited by applicant]
US 20190183220A1 · Takada · 2019 [cited by applicant]
US 20190183820A1 · Millet · 2019 [cited by applicant]
US 20190183821A1 · Millet · 2019 [cited by applicant]
US 20190191755A1 · Garvey et al. · 2019 [cited by applicant]
US 20190209501A1 · Tinsley, M. et al. · 2019 [cited by applicant]
US 20190255028A1 · Lowery et al. · 2019 [cited by applicant]
US 20190262293A1 · Millet · 2019 [cited by applicant]
US 20190313682A1 · Nagel · 2019 [cited by applicant]
US 20190321309A1 · Millet · 2019 [cited by applicant]
US 20200030266A1 · Bradley et al. · 2020 [cited by applicant]
US 20200061004A1 · Millet · 2020 [cited by applicant]
US 20200078973A1 · Valeze et al. · 2020 [cited by applicant]
US 20200129463A1 · Lowery et al. · 2020 [cited by applicant]
US 20200140371A1 · Verdin et al. · 2020 [cited by applicant]
US 20200170982A1 · Millet · 2020 [cited by examiner]
US 20200253909A1 · Millet · 2020 [cited by applicant]
US 20200268701A1 · D'Agostino et al. · 2020 [cited by applicant]
US 20210095867A1 · Gururaja et al. · 2021 [cited by applicant]
US 20210106168A1 · Cingolani et al. · 2021 [cited by applicant]
US 20210205241A1 · Millet · 2021 [cited by applicant]
US 20220133673A1 · Millet · 2022 [cited by applicant]
US 20220202760A1 · Greenwood et al. · 2022 [cited by applicant]
US 20230072854A1 · Purpura et al. · 2023 [cited by applicant]
US 20230115966A1 · Wells et al. · 2023 [cited by applicant]
US 20230201145A1 · Millet · 2023 [cited by applicant]
US 20240024265A1 · Millet · 2024 [cited by applicant]
CA 2990927A1 · 2018 [cited by applicant]
CN 86108978A · 1987 [cited by applicant]
CN 1256629A · 2000 [cited by applicant]
CN 1347319A · 2002 [cited by applicant]
CN 1104978C · 2003 [cited by applicant]
CN 1184978C · 2005 [cited by applicant]
CN 1972698A · 2007 [cited by applicant]
CN 101674730A · 2010 [cited by applicant]
CN 101678043A · 2010 [cited by applicant]
CN 101969769A · 2011 [cited by applicant]
CN 102164884A · 2011 [cited by applicant]
CN 104224823A · 2014 [cited by applicant]
CN 105050594A · 2015 [cited by applicant]
CN 106038532A · 2016 [cited by applicant]
CN 106459646A · 2017 [cited by applicant]
CN 106858066A · 2017 [cited by applicant]
CN 108253621A · 2018 [cited by applicant]
CN 109480284A · 2019 [cited by applicant]
CN 111867576A · 2020 [cited by applicant]
CN 112262936A · 2021 [cited by applicant]
DE 102017210992A1 · 2019 [cited by applicant]
EP 0008700A1 · 1980 [cited by applicant]
EP 1112711A1 · 2001 [cited by applicant]
EP 1178748A1 · 2002 [cited by applicant]
EP 1827412A1 · 2007 [cited by applicant]
EP 1915144A2 · 2008 [cited by applicant]
EP 2283834A2 · 2011 [cited by applicant]
EP 1755743B1 · 2013 [cited by applicant]
EP 2976073A1 · 2016 [cited by applicant]
EP 3094321A1 · 2016 [cited by applicant]
EP 3366173A2 · 2018 [cited by applicant]
EP 3446045A1 · 2019 [cited by applicant]
FR 2997302A1 · 2014 [cited by applicant]
GB 2391493A · 2004 [cited by applicant]
ID 201701176 · 2017 [cited by applicant]
JP 11060434A · 1999 [cited by applicant]
JP 2002521330A · 2002 [cited by applicant]
JP 2004035417A · 2004 [cited by applicant]
JP 5030553B2 · 2012 [cited by applicant]
JP 2015042644A · 2015 [cited by applicant]
JP 5690261B2 · 2015 [cited by applicant]
JP 2015514104A · 2015 [cited by applicant]
JP 2015102323A · 2015 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
JP 2016121128A · 2016 [cited by applicant]
JP 2017046688A · 2017 [cited by applicant]
JP 2018158897A · 2018 [cited by applicant]
JP 2020502652A · 2020 [cited by applicant]
JP 2020527583A · 2020 [cited by applicant]
JP 2021504476A · 2021 [cited by applicant]
JP 2021506294A · 2021 [cited by applicant]
RU 2345546C2 · 2009 [cited by applicant]
WO 8703808A1 · 1987 [cited by applicant]
WO 9841200A1 · 1998 [cited by applicant]
WO 0004895A2 · 2000 [cited by applicant]
WO 0015216A1 · 2000 [cited by applicant]
WO 0069315A1 · 2000 [cited by applicant]
WO 0370823A2 · 2003 [cited by applicant]
WO 2005077348A1 · 2005 [cited by applicant]
WO 2005107724A1 · 2005 [cited by applicant]
WO 2006029577A1 · 2006 [cited by applicant]
WO 2006061624A1 · 2006 [cited by applicant]
WO 2007115282A2 · 2007 [cited by applicant]
WO 2007138322A1 · 2007 [cited by applicant]
WO 2008005818A1 · 2008 [cited by applicant]
WO 2008021394A2 · 2008 [cited by applicant]
WO 2008024408A2 · 2008 [cited by applicant]
WO 2009089144A1 · 2009 [cited by applicant]
WO 2010021766A1 · 2010 [cited by applicant]
WO 2010104595A1 · 2010 [cited by applicant]
WO 2011101171A1 · 2011 [cited by applicant]
WO 2012019295A1 · 2012 [cited by applicant]
WO 2012024611A1 · 2012 [cited by applicant]
WO 2013057506A1 · 2013 [cited by applicant]
WO 2013150153A1 · 2013 [cited by applicant]
WO 2014153415A2 · 2014 [cited by applicant]
WO 2014153416A1 · 2014 [cited by applicant]
WO 2015063140A1 · 2015 [cited by applicant]
WO 2015071811A1 · 2015 [cited by applicant]
WO 2015156865A1 · 2015 [cited by applicant]
WO 2016123229A1 · 2016 [cited by applicant]
WO 2016149687A1 · 2016 [cited by applicant]
WO 2017156446A1 · 2017 [cited by applicant]
WO 2017165443A1 · 2017 [cited by applicant]
WO 2017165445A1 · 2017 [cited by applicant]
WO 2017182664A1 · 2017 [cited by applicant]
WO 2017184788A1 · 2017 [cited by applicant]
WO 2017208217A2 · 2017 [cited by applicant]
WO 2018055388A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018114309A1 · 2018 [cited by applicant]
WO 2018132189A1 · 2018 [cited by applicant]
WO 2018175879A1 · 2018 [cited by applicant]
WO 2018187324A1 · 2018 [cited by applicant]
WO 2018187852A1 · 2018 [cited by applicant]
WO 2019018683A1 · 2019 [cited by applicant]
WO 2019108683A1 · 2019 [cited by applicant]
WO 2019118624A1 · 2019 [cited by applicant]
WO 2019200132A1 · 2019 [cited by applicant]
WO 2019204148A1 · 2019 [cited by applicant]
WO 2019237152A1 · 2019 [cited by applicant]
WO 2019237185A1 · 2019 [cited by applicant]
WO 2020041871A1 · 2020 [cited by applicant]
WO 2020092451A1 · 2020 [cited by applicant]
WO 2021178547A1 · 2021 [cited by applicant]
WO 2022040644A2 · 2022 [cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/. [cited by applicant]
O'Mailey et al, Appl. Physiol. Nutr. Metab. 42: 1031-1035 (2017) Published at www.NRCRESEARCHPRESS.com/APNM on Jul. 27, 2017. [cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits.com.au/ketosis-can-we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017). [cited by applicant]
Office Action received for European Patent Application No. 19788264.0, mailed on Mar. 13, 2024, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 20805593.9, mailed on Dec. 22, 2023, 7 pages. [cited by applicant]
Paraxanthine-Pubchem—2023 (Year: 2023). [cited by applicant]
Parker, Steve, “Ketogenic Mediterraanean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010). [cited by applicant]
PCT International Search Report and Written Opinion issued by the International Searching Authority on Jul. 15, 2014 or International Patent Application No. PCT/US2014/031237. [cited by applicant]
Pete J Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9. [cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin' La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15… [cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019. [cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions In Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (… [cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373. [cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011). [cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982. [cited by applicant]
Sajewicz et al. In Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010). [cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial… [cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017). [cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R. [cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm. [cited by applicant]
Shigeno etal. in Biosci. Biotech. Biochem., 56(2), 320-323 (1992) (Year: 1992). [cited by applicant]
Short, Jay, Effects of A Ketone/Caffeine Supplement on Cycling and Cognitive Performance, Master's thesis, Ohio State University, 61 pages, (Jan. 1, 2017). [cited by applicant]
Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits, 2013, Nutrients, 5: 1417-1425 (Year: 2013). [cited by applicant]
Sorensen et al. (“Simultaneous determination of ß-hydroxybutyrate and ß-hydroxy-ß-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry”, Clinical … [cited by applicant]
Stubbs et al., “On the Metabolism of Exogenous Ketones in Humans”, frontiers in Physiology, vol. 8, 2017, 13 pages. [cited by applicant]
Tanaka, J., et al., “Significance of Blood Ketone Body Ration as an indicator of Hepatic Cellular Energy Status in Jaundiced Rabbits”, Gastroenterology, 1979, vol. 76, No. 4, pp. 691-696. [cited by applicant]
The Medical Republic, 2018, Sustained Release Sodium Butyrate Supplement Now Available to Support Management of GI Disorders, https://medicalrepublic.com.au/sustained-release-sodium-butyrate-supplement-now-available-sup… [cited by applicant]
Tisdale, “Reduction of weight loss and tumour size in a cachexia model by a high fat diet”, British Journal of Cancer, Jul. 1987, vol. 56, p. 39-43. [cited by applicant]
Tsai et al., “Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes” life Sciences 78(2006) pp. 1385-1391. [cited by applicant]
Vandenberghe et al. in Can. J. Physiol. Pharmacol. 95: 455-458 (2017) (Published at www.nrcresearchpress.com/cjpp on Nov. 25, 2016). (Year: 2016). [cited by applicant]
Veech, “The Therapeutic Implications of Ketone Bodies: The Effects of Ketone Bodies in Pathological Conditions: Ketosis, Ketogenic Diet, Redox States, Insulin Resistance, and Mitochondrial Metabolism”, Prostaglandins Le… [cited by applicant]
Veech, et al., “Ketone Bodies Mimic the Life Span Extending Properties of Caloric Restriction”, IUBMB Life Feb. 8, 2017. [cited by applicant]
Vorgerd, M. and J. Zange. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myologica, 2007; XXVI; pp. 61-63. [cited by applicant]
Walton, G. et al. A randomised, double-blind, placebo controlled cross-over study to determine the gastrointestinal effects of consumption of arabinoxylan-oligosaccharides enriched bread in healthy volunteers, 2012, Nut… [cited by applicant]
WO2009045481, Pan et al. Published Apr. 9, 2009 Listed in this section as citation type “foreign” does not allow for any appropriate country code for “WO” documents. [cited by applicant]
Written Opinion cited in PCT/US19/27214 dated Jun. 25, 2019. [cited by applicant]
Wu et al., “Medium-Chain Triglycerides in Infant Formulas and Their Relation to Plasma Ketone Body Concentrations,” Pediatric Research, vol. 20, No. 4, (1986), pp. 338-341. [cited by applicant]
Yang Y. et al., Role of Adherent-Invasive [cited by applicant]
Yang Yue et al., Research on sarcopemc obesity , Chinese Journal of Modern Medicine, vol. 20, No., 3, Mar. 25, 2018, pp. 98-101. [cited by applicant]
Yang Zeyi, “Biochemistry of sports nutrition scientific research progress”, Mar. 31, 2004, vol. 23, No. 2, pp. 158-165. [cited by applicant]
Zaleski, A. et al., Butyric acid in irritable bowel syndrome, 2013, Prz Gastroenterol, 8(6), 350-353 (Year: 2013). [cited by applicant]
Zeng Jing et al., “B-hydroxy-3-methyl—The clinical effects and mechanism”, vol. 2, No. 2, Jun. 9, 2015, pp. 57-62. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/017078, mailed on Aug. 18, 2022, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/045186, mailed on Mar. 9, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/050302, mailed on Mar. 2, 2023, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2021/063559, mailed on Jul. 6, 2023, 6 pages. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US19/48357 dated Nov. 18, 2019. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US19/48364 dated Nov. 15, 2019. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/16952 dated Apr. 22, 2020. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/17552 dated May 4, 2020. [cited by applicant]
International Search Report and Written Opinion issued in PCT/US20/17556 dated May 4, 2020. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/062093, mailed on Feb. 1, 2019, 7 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US20/017555, mailed on May 4, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US20/37289, mailed or Sep. 30, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/031237, mailed on Jul. 15, 2014, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2017/021886, mailed on Jun. 1, 2017, 15 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/062096, mailed on Feb. 11, 2019, 13 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/048357, mailed on Nov. 18, 2019, 13 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/016952, mailed on Apr. 22, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/017552, mailed on May 4, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/017556, mailed on May 4, 2020, 12 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/033159, mailed on Aug. 12, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/063559, mailed on Mar. 18, 2022, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/045186, mailed on Nov. 22, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/17078, mailed on Apr. 23, 2021, 9 pages. [cited by applicant]
International Search Report cited in PCT/US18/62093 dated Feb. 1, 2019. [cited by applicant]
International Search Report cited in PCT/US19/27214 dated Jun. 25, 2019. [cited by applicant]
Invitation to Respond to Written Opinion issued by the Intellectual Property Office of Singapore dated Dec. 28, 2016 for corresponding Singapore Patent Application No. 11201506780R. [cited by applicant]
It Really is in Your Blood: Glucose to Ketone Ratios. Greymadder, Sep. 15, 2014. Downloaded Apr. 1, 2015. http://greymadder.net/2014/09/15/it-really-is-in-your-blood-glucose-to-ketone-ratios/. [cited by applicant]
James, “Optical Purity and Enantiomeric Excess” at https://www.masterorganicchemistry.com/2017/02/24/optical-purity-and-enantiomeric-excess/. (Retrieved from the internet Nov. 6, 2018) (Year: 2018). [cited by applicant]
John C Newman et al: “beta-Hydroxybutyrate: A Signaling Metabolite”, Annual Review of Nutrition, vol. 37, Aug. 21, 2017 (Aug. 21, 2017), pp. 51-76, XP055771586. [cited by applicant]
Karppanen et al, J. Human Hypertension (2005), vol. 19, pp. S10-S19. (Year: 2005). [cited by applicant]
Karppanen, H., et al, “Why and how to implement sodium, potassium, calcium, and magnesium changes in food items and diets?” J. Human Hypertension (2005), vol. 19, pp. S10-S19. [cited by applicant]
Kaster M.P. et al., “Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress”, Proceedings of the National Academy of Sciences, vol. 112, No. 25, Jun. 8,… [cited by applicant]
Kesl, et al., “Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Spraque-Dawley rats”, Nutrition & Metabolism (2016). [cited by applicant]
Kim Do Young et al., “Ketone bodies are protective against oxidative stress in neocortical neurons,” Journal of Neurochemistry, vol. 101, Issue 5, Jun. 1, 2007, pp. 1316-1326. [cited by applicant]
Kirsch, Jr et al. “Butanediol Induced Ketosis Increases Tolerance to Hypoxia in the Mouse.” Stroke. 1980, vol. 11, No. 3, pp. 506-513. [cited by applicant]
Kossoff, Eric H. et al. “Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group.” Epilepsia, Feb. 2009;50(2):304-17. Epub Sep. 23, 2008. [cited by applicant]
Krotkiewski, “Value of VLCD Supplementation with Medium Chain Triglycerides”, Int J Obes Relat Metab Disord, Sep. 2001, 25(9), pp. 1393-1400. [cited by applicant]
Lang Chaochun, “Healthy fitness and exercise prescription”, Nov. 30, 2013, p. 201. [cited by applicant]
Lile et al. Drug Alcohol Depend. 2012, 122 (1-2), 61-69. [cited by applicant]
Lonza, Duocap Capsules, Feb. 16, 2018, https ://web .archive.org/web/20180216001656/https://www.capsugel.com/consumer-health-nutrition-products/duocap-capsules (Year: 2018). [cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieved from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15. [cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491. [cited by applicant]
Maalouf Met al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar. … [cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315. [cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev… [cited by applicant]
Malo, M. S. et. al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010). [cited by applicant]
Mangels D.R. et al, “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763. [cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, No. 30 Dec. 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005). [cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956. [cited by applicant]
A New Toy Measuring Blood Ketones. Diet Doctor, Aug. 21, 2012. Dowloaded Apr. 1, 2015. http://www.dietdoctor.com/a-new-toy-measuring-blood-ketoones. [cited by applicant]
Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions in Vivo, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (Apr. 1, 2002)… [cited by applicant]
Amazon, “Perfect Keto Perform Pre Workout Powder—Bum Fat for Fuel Energy Supplement Drink Mix for Men and Women—Keto Friendly with Ketone Salts, BCAA, Nitric Oxide & MCT”, Sep. 25, 2017 entire document especially p. 1 R… [cited by applicant]
Anonymous: “Strawberry Pineapple Flavour Pre-Exertion Performance Optimizer”, MINTEL, Database accession No. 5661617, 2018, pp. 4. [cited by applicant]
Arendash et al. “Caffeine and Coffee as Therapeutics Against Alzheimer's Disease”, Journal of Alzheimer's Disease 20, 2010, S117-S126. [cited by applicant]
Arnold, Instant Ketosis?, (2013), Aug. 4, 2013 (retrieved on Apr. 21, 2017), p. 1-3. Retrieved from the internet; URL: <http://patrickarnoldblog.com/instant-ketosis/. (Year: 2013). [cited by applicant]
Bala et al. Drug Invention Today. Jun. 1, 2018;10(6), 929-931. [cited by applicant]
Bastin et al., “Salt Slection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, American Chemical Society and The Royal Society of Chemistry, vol. 4, No. 5, 2000, pp. 427-435. [cited by applicant]
Blazquez et al. Journal of Neurochemistry, 1999, vol. 72 No. 4, pp. 1759-1768. (Year: 1999). [cited by applicant]
Budin. N. et al., “Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S, S) enantiomer,” Bioorganic Chemistry, vol. 80, Oct. 2018, pp. 560-564. [cited by applicant]
Clarke, et al., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. Aug. 2012;63(3):401-8. [cited by applicant]
Craciun, S. et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme, 2012, PNAS, 109(52): 21307-21312 (Year: 2012). [cited by applicant]
Cresci, G. et al., Lactobacillus GG and Tributyrin Supplementation Reduce Antibiotic-Induced Intestinal Injury, 2013, Journal of Parenteral and Enteral Nutrition, 37(6), 1-20 (Year: 2013). [cited by applicant]
Daniells, Stephen, ‘This is caffeine-evolved’: Ingenious Ingredients co-founder talks up potential of paraxanthine, Nov. 3, 2021, 2 pages, retrieved from https://www.nutraingredients-usa.com/Article/2021/11/03/This-is-c… [cited by applicant]
Database GNPD Mintel, Sep. 29, 2016, anonymous, “Blue Lemon Ice Advanced Formula”, XP093048090, Database accession No. 4315637, pp. 3. [cited by applicant]
Dietary Guidelines Recommendations at https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/ appendix-7/ (2010) (retrieved from the internet Oct. 20, 2020) (Year: 2010). [cited by applicant]
Dolson, Laura. How to Test Your Blood for Ketones. Downloaded Apr. 1, 2015. http://lowcarbdiets.about.com/od/KetogenicDiets/a/How-to-Test-Blood-For-Ketones.htm. [cited by applicant]
European Search Report received for EP Patent Application No. 20755289.4, mailed on Oct. 11, 2022, 7 pages. [cited by applicant]
Cited By (2)
US 12,514,841 US 12,622,889